Riverbridge Partners LLC Trims Stock Holdings in Haleon plc (NYSE:HLN)

Riverbridge Partners LLC lessened its holdings in shares of Haleon plc (NYSE:HLN) by 30.1% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 15,363 shares of the company’s stock after selling 6,628 shares during the quarter. Riverbridge Partners LLC’s holdings in Haleon were worth $147,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. FMR LLC grew its position in shares of Haleon by 5.8% during the third quarter. FMR LLC now owns 104,918,269 shares of the company’s stock worth $1,110,035,000 after buying an additional 5,768,117 shares in the last quarter. Sculptor Capital LP increased its position in shares of Haleon by 67.8% in the 2nd quarter. Sculptor Capital LP now owns 8,887,098 shares of the company’s stock worth $73,407,000 after purchasing an additional 3,592,000 shares during the last quarter. Clearbridge Investments LLC raised its stake in shares of Haleon by 8.6% in the 2nd quarter. Clearbridge Investments LLC now owns 41,753,987 shares of the company’s stock valued at $344,888,000 after purchasing an additional 3,307,009 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of Haleon by 49.9% during the third quarter. Wellington Management Group LLP now owns 9,152,490 shares of the company’s stock worth $96,833,000 after purchasing an additional 3,046,841 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its stake in Haleon by 25.3% in the third quarter. JPMorgan Chase & Co. now owns 5,084,202 shares of the company’s stock worth $53,791,000 after purchasing an additional 1,026,939 shares in the last quarter. 6.67% of the stock is owned by institutional investors and hedge funds.

Haleon Trading Up 1.9 %

Shares of NYSE HLN opened at $9.40 on Friday. Haleon plc has a 12-month low of $7.89 and a 12-month high of $10.80. The company has a market cap of $42.53 billion, a price-to-earnings ratio of 27.63, a price-to-earnings-growth ratio of 2.62 and a beta of 0.29. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. The stock’s 50 day simple moving average is $9.54 and its 200 day simple moving average is $9.72.

Haleon (NYSE:HLN) last posted its earnings results on Thursday, October 31st. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.03. The company had revenue of $3.62 billion for the quarter, compared to analysts’ expectations of $3.74 billion. Haleon had a return on equity of 14.76% and a net margin of 10.85%. During the same period last year, the business posted $0.10 earnings per share. Equities research analysts expect that Haleon plc will post 0.44 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have commented on HLN. Sanford C. Bernstein downgraded Haleon from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 8th. Morgan Stanley cut Haleon from an “overweight” rating to an “equal weight” rating in a research note on Friday, January 10th. Finally, UBS Group upgraded shares of Haleon to a “strong-buy” rating in a research note on Tuesday, October 1st. Three investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $10.95.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.